Compare prices and buy Methylcobalamin from 4 research peptide vendors - also called suppliers or sources. Updated daily.
Methylcobalamin (CAS 13422-55-4) is the methyl-bearing coenzyme form of vitamin B12, a cobalt-containing corrinoid rather than a peptide. It is the cofactor of methionine synthase, which transfers a methyl group from 5-methyltetrahydrofolate to homocysteine to regenerate methionine, linking the folate cycle to S-adenosylmethionine production. Unlike cyanocobalamin and hydroxocobalamin, it has no approved drug application listed in Drugs@FDA. Indexed separately from generic Vitamin B12 listings, which often do not state the form.
For research purposes only. Not medical advice.
Listed prices for in-stock single vials, before coupon codes. Kits are left out.
Methylcobalamin is not a peptide. It is one of the four forms of vitamin B12, a cobalt-containing corrinoid, and PeptideScouter catalogues it because research-peptide vendors sell it from the same catalogs as their peptides. The Vitamin B12 page covers what the forms share: the corrin core, each form's CAS number, how cells process them and the two enzymes they serve. This page covers what is specific to the methyl form.
Its distinguishing feature is a methyl group bound directly to the cobalt atom through a cobalt-carbon bond (Lodowski et al., Journal of Physical Chemistry A, 2014). Its drug name is mecobalamin, the name used by the Japanese Pharmacopoeia and the US Adopted Names program (KEGG DRUG D03246), and the WHO's ATC index files it under that name as B03BA05, in the vitamin B12 group.
That cobalt-carbon bond is what light breaks. A computational study of methylcobalamin's photolysis identified two pathways for the cleavage, one associated with visible-light excitation and one with near-ultraviolet excitation (Lodowski, 2014). In a comparison of four cobalamins in solution under UVA light, all were photolabile, methylcobalamin and adenosylcobalamin converted to hydroxocobalamin within seconds, and hydroxocobalamin was the most stable (Juzeniene and Nizauskaite, Journal of Photochemistry and Photobiology B, 2013).
Eisai, which markets the compound in Japan, states that mecobalamin "is chemically unstable when exposed to light" and supplies its ALS product as a freeze-dried formulation in light-proof vial packaging (Eisai, October 2024).
Eisai markets mecobalamin in Japan as Methycobal, an injection indicated for peripheral neuropathies and for megaloblastic anemia caused by vitamin B12 deficiency, and as tablets and fine granules indicated for peripheral neuropathies (Eisai, September 2024).
On September 24, 2024, Japan approved Eisai's Rozebalamin, an injectable mecobalamin, for "slowing progression of functional impairment in amyotrophic lateral sclerosis" (ALS). The product had held orphan drug designation since May 2022, and Eisai filed in January 2024.
The approval came after an earlier application was withdrawn. Eisai's Phase 2/3 Study 761 randomized 373 ALS patients to placebo or one of two dose levels and found no significant difference on either primary endpoint, time to death or full ventilation support and change in the revised ALS Functional Rating Scale (ALSFRS-R) score by week 182. A post hoc analysis of patients who entered within 12 months of symptom onset favored treatment on both (Kaji et al., Journal of Neurology, Neurosurgery and Psychiatry, 2019). Eisai filed on those results in May 2015 and withdrew the application in March 2016 after meetings with the Pharmaceuticals and Medical Devices Agency (PMDA) found the package insufficient for approval.
JETALS, the trial behind the approval, was an investigator-initiated Phase 3 study led by Tokushima University with support from the Japan Agency for Medical Research and Development, and Eisai supplied the study drug (Oki et al., JAMA Neurology, 2022). Its ClinicalTrials.gov record, NCT03548311, lists Eisai as lead sponsor and the University of Tokushima as collaborator.
Eisai expresses the same result as slowing decline by approximately 43%. The authors frame their conclusion around early-stage patients with a moderate progression rate and the 16-week treatment period, and the approval covers the licensed Rozebalamin product, not research-grade methylcobalamin.
The US has approved no methylcobalamin drug, the opposite of its status in Japan. Drugs@FDA holds no application under either name. For compounding, FDA's bulk drug substance nomination lists place it as follows, as of October 2026.
A listing labelled by its total mass carries a price per milligram, and one sold by volume does not.
Yes. Mecobalamin is the drug name for methylcobalamin, used by the Japanese Pharmacopoeia and the US Adopted Names program, and the WHO's ATC index lists it as mecobalamin under code B03BA05, in the vitamin B12 group. Eisai's Japanese products Methycobal and Rozebalamin contain mecobalamin. Vendor titles such as B12 (Methylated) refer to the same compound.
No. Drugs@FDA holds no application for methylcobalamin or mecobalamin. For compounding, FDA lists methylcobalamin in Category 1, under evaluation, of both its Section 503A nominations (updated May 14, 2026) and its Section 503B nominations (updated March 21, 2025), and in neither pathway's Category 2.
JETALS was an investigator-initiated Phase 3 trial led by Tokushima University and published in JAMA Neurology in 2022. It randomized 130 patients diagnosed within a year of ALS onset to methylcobalamin or placebo for a 16-week randomized period. In the full analysis set, the revised ALS Functional Rating Scale score fell 2.66 points with methylcobalamin and 4.63 points with placebo, a least-squares mean difference of 1.97 points (P = .01). Adverse events occurred at similar rates in both groups. The trial was the basis for Rozebalamin's approval in Japan in 2024.
Yes. Its methyl group is bound to cobalt through a cobalt-carbon bond, and light cleaves that bond. In a 2013 study of four cobalamins in solution, methylcobalamin converted to hydroxocobalamin within seconds of UVA exposure, while hydroxocobalamin was the most stable form. Eisai describes mecobalamin as chemically unstable when exposed to light and supplies its Japanese ALS product in light-proof vial packaging.
A methylcobalamin listing labelled by its total mass carries a price per milligram. A listing sold by volume, in milliliters, carries no per-milligram figure, so it appears in the price table but on no per-milligram ranking.
Methylcobalamin is sold by 4 research peptide vendors indexed on PeptideScouter. The lowest listed in-stock prices are at ION Peptide ($7.50/mg). The table above compares all 4 tracked listings by vendor, refreshed daily.
3 of the 4 indexed vendors currently have Methylcobalamin in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
ION Peptide currently lists Methylcobalamin at $7.50/mg, the lowest listed price across 4 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $6.38/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 4 vendors listing Methylcobalamin publish a PeptideScouter code, worth 10% to 15% off. Applied, the lowest effective price falls from $7.50/mg listed to $6.38/mg at ION Peptide. Each vendor's code is shown beside its price in the table above.
10 mg vials list from $75.00 (median $75.00 across 1 in-stock listing). Prices are refreshed daily.
Methylcobalamin's CAS Registry Number is 13422-55-4. It is also sold as B12 (Methylated), Vitamin B12 (Methylcobalamin).